PROMETHEUS BIOSCIENCES INC (RXDX)       36.06  -1.66 (-4.4%)

36.06  -1.66 (-4.4%)

US74349U1088 - Common Stock - After market: 36.06 0 (0%)

PROMETHEUS BIOSCIENCES INC36.06

NASDAQ:RXDX (12/6/2022, 7:01:51 PM)-1.66 (-4.4%)

After market: 36.06 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-09 2022-11-09/amc Earnings (Next) N/A N/A
Ins Owners 0.04% Inst Owners 79.77%
Market Cap 1.51B Shares 41.94M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 88.24
IPO 03-11 2021-03-11

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RXDX Daily chart

Company Profile

Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 72 full-time employees. The company went IPO on 2021-03-11. The firm is engaged in discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, such as inflammatory bowel disease (IBD). The firm's precision medicine platform Prometheus360, which includes gastrointestinal (GI) bioinformatics databases, to identify therapeutic targets and develop therapeutic candidates to engage the targets. Its product pipeline includes PRA023, PR600, PR300, PR1100, PR1800 and PR2100. The firm's lead product candidate PRA023, is an IgG1 humanized monoclonal antibody (mAb) designed to target both inflammation and fibrosis associated with IBD. The company has focused on developing PRA023 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).

Company Info

PROMETHEUS BIOSCIENCES INC

3050 Science Park Road, #342

San Diego CALIFORNIA 92121

P: 18584224300.0

CEO: Mark C. McKenna

Employees: 72

Website: https://www.prometheusbiosciences.com/

RXDX News

News Imagea day ago - Market News VideoNotable Monday Option Activity: RXDX, GPRE, GHNews Image5 days ago - The Motley FoolWhy Shares of Prometheus Biosciences Slumped This Week

The company's lead pipeline candidate is facing competition from a Pfizer-backed drug.

News Image19 days ago - Market News VideoPrometheus Biosciences Becomes Oversold (RXDX)News Image19 days ago - Market News VideoNotable Thursday Option Activity: CZR, RXDX, IBMNews Imagea month ago - Prometheus BiosciencesPrometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 - - Initiation of Phase 1 trial of second precision...

News Imagea month ago - Prometheus BiosciencesPrometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

RXDX Twits

Here you can normally see the latest stock twits on RXDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example